{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:38:38Z","timestamp":1788903518529,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.bulcan.2016.05.007","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:05:09Z","timestamp":1466726709000},"page":"643-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nouvelles classifications mol\u00e9culaires du cancer colorectal, du cancer du pancr\u00e9as et du cancer de l\u2019estomac\u00a0: vers un traitement \u00e0 la carte\u00a0?"],"prefix":"10.1016","volume":"103","author":[{"given":"Chantal","family":"Dreyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9847-4594","authenticated-orcid":false,"given":"Pauline","family":"Afchain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Trouilloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2016.05.007_bib0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0075","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1\u00a0blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0080","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2016.01.009","article-title":"Targeting the MET pathway in gastric and oesophageal cancers: refining the optimal approach","author":"Lee","year":"2016","journal-title":"Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2016.05.007_bib0090","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0105","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stages II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0110","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0115","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2016.05.007_bib0120","doi-asserted-by":"crossref","first-page":"djv362","DOI":"10.1093\/jnci\/djv362","article-title":"Treatment algorithms based on tumor molecular profiling: the essence of precision medicine trials","volume":"108","author":"Le Tourneau","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2016.05.007_bib0125","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profi ling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2\u00a0trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2016.05.007_bib0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrclinonc.2016.31","article-title":"Equal access to innovative therapies and precision cancer care","volume":"13","author":"Buzyn","year":"2016","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116300881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116300881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T21:56:51Z","timestamp":1536616611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455116300881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":13,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0007455116300881"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.05.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles classifications mol\u00e9culaires du cancer colorectal, du cancer du pancr\u00e9as et du cancer de l\u2019estomac\u00a0: vers un traitement \u00e0 la carte\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}